Normal human urine contains large numbers of exosomes, which are 40-to 100-nm vesicles that originate as the internal vesicles in multivesicular bodies from every renal epithelial cell type facing the urinary space. Here, we used LC-MS/MS to profile the proteome of human urinary exosomes. Overall, the analysis identified 1132 proteins unambiguously, including 177 that are represented on the Online Mendelian Inheritance in Man database of disease-related genes, suggesting that exosome analysis is a potential approach to discover urinary biomarkers. We extended the proteomic analysis to phosphoproteomic profiling using neutral loss scanning, and this yielded multiple novel phosphorylation sites, including serine-811 in the thiazide-sensitive Na-Cl co-transporter, NCC. To demonstrate the potential use of exosome analysis to identify a genetic renal disease, we carried out immunoblotting of exosomes from urine samples of patients with a clinical diagnosis of Bartter syndrome type I, showing an absence of the sodium-potassium-chloride co-transporter 2, NKCC2. The proteomic data are publicly accessible at http://dir.nhlbi.nih.gov/papers/lkem/exosome/.
Urinary exosomes are small extracellular vesicles (Ͻ100 nm in diameter) that originate from the internal vesicles of multivesicular bodies (MVB) in renal epithelial cells, including glomerular podocytes, renal tubule cells, and the cells lining the urinary drainage system. 1 Exosomes are released into the urine when the outer membrane of the MVB fuses with the apical plasma membrane of the epithelial cell.
Exosomes can be recovered from the urine by differential centrifugation as a low-density membrane fraction. Exosome isolation can result in marked enrichment of low-abundance urinary proteins that have potential pathophysiologic significance. As a consequence, we and others have been working to define optimal conditions for their isolation and purification as a prelude to their use in biomarker discovery studies. [1] [2] [3] In this study, we thoroughly expanded the known proteome of human urinary exosomes by using a highly sensitive LC-MS/MS system, improved software for identification of peptide ions and a more elaborate data analysis strategy than in our previous study. In addition, we used a neutral loss scanning approach 4 to investigate the phosphoproteome of human urinary exosomes. The study identified 1412 proteins including 14 phos-phoproteins in human urinary exosomes. Overall, there are 177 proteins that are associated with diseases as judged by their presence on the Online Mendelian Inheritance in Man (OMIM) database, 34 of which are known to be associated with renal diseases. The potential clinical usefulness of urinary exosomes was demonstrated using the well-defined renal tubulopathy, Bartter syndrome type I, as an example. The rich information from the proteomic analysis also provides further insight into the biogenesis of urinary exosomes.
RESULTS

Large-Scale Proteomic Profiling of Human Urinary Exosomes
In this study, we carried out proteomic profiling of a lowdensity membrane fraction from human urine consisting chiefly of exosomes, using a highly sensitive LC-MS/MS system, based on an ion trap mass spectrometer (LTQ; ThermoFinnigan; Thermo Electron, San Jose, CA). We unambiguously identified 1132 proteins including 205 proteins seen in our previous study and 927 proteins not seen in our previous study of human urinary exosomes. 1 The full list (ambiguous and unambiguous identifications) contains 1412 proteins and can be viewed in Supplemental Table 1 , and the list of proteins that were unambiguously identified in both studies can be viewed at http://dir.nhlbi.nih.gov/papers/lkem/exosome/. The expanded list of exosomal proteins includes 177 proteins that are disease related, on the basis of their presence in the OMIM database (Table 1) .
Predictably, a large number of proteins that were identified were integral membrane proteins involved in solute and water transport ( Table 2 ). As seen in our previous study, 1 these proteins predominantly represent apical transporters present in every renal tubule segment, including the proximal tubule (sodium-hydrogen exchanger 3, sodium-glucose co-transporter 1 and 2, and aquaporin-1 [AQP1]), the thick ascending limb (sodium-potassium-chloride co-transporter 2 [NKCC2]), the distal convoluted tubule (thiazide-sensitive Na-Cl co-transporter [NCC]), and connecting tubule/collecting duct (AQP2, rhesus blood group C glycoprotein [RhCG, an ammonia channel], B1 subunit of vacuolar H ϩ -ATPase, and pendrin). Note that both polycystin-1 and polycystin-2 were detected in human urinary exosomes.
Exosomes derive from MVB and are delivered to the urine when the outer membranes of MVB fuse with the apical plasma membrane. Interestingly, 22 of the proteins identified in this study are recognized as components of the apparatus responsible for the formation of MVB (Table 3 ). These 22 proteins account for approximately 75% of the proteins that constitute the ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III complexes involved in multivesicular body formation. 5 In addition, 17 proteins identified in this study are subunits of the human vacuolar H ϩ -ATPase (Table 4) . Vacuolar H ϩ -ATPases are ATP-dependent proton pumps for proton transport into intracellular organelles. 6 These proteins also mediate proton transport across the apical plasma membrane of type A intercalated cells and across the basolateral plasma membrane of type B intercalated cells. 7 The B1 subunit is selectively expressed in intercalated cells, and its detection in urinary exosomes establish that intercalated cells secrete exosomes as do other types of epithelial cells lining the renal tubule. These proteins constitute 78% of the subunits of the V 0 and V 1 domains of the vacuolar H ϩ -ATPase. 8 An example of the utility of exosome analysis is shown in Figure 1 , describing immunoblotting in patients with Bartter syndrome type I, associated with mutations in the SLC12A1 gene, which encodes for the NKCC2 sodium-potassium-chloride cotransporter protein. 9 The NKCC2 protein was found in the proteome of the human urinary exosomes as shown in Table 1 . Urine samples were obtained from two patients (patients 1 and 2) with clinical phenotypes consistent with Bartter syndrome type I (Figure 1A) . 10 The clinical diagnosis for the patients with Bartter syndrome type I was confirmed by the ultrasound images showing deposits of calcium in the kidney also known as nephrocalcinosis 9,10 ( Figure 1B ) and other typical laboratory findings. The two urinary exosome samples obtained from the patients with Bartter syndrome type I were analyzed by immunoblotting for the presence of the NKCC2 protein ( Figure 1C) . Compared with the respective control samples, patients 1 and 2 showed an absence of the NKCC2 protein bands, expected at 160 kD for monomeric NKCC2 and 320 kD for dimeric NKCC2. In addition, the samples (patients 1 and 2) were probed for the thiazide-sensitive co-transporter (NCC) protein to ensure that urinary exosomes were successfully isolated and loaded properly. Strong NCC bands were obtained in samples from both patients with Bartter syndrome type I and control samples.
Phosphoproteomic Analysis of Human Urinary Exosomes
Protein phosphorylation is a key element of most cell regulatory processes. Recently, technical approaches that allow phosphoproteomic profiling on a large scale have been introduced. 4, [11] [12] [13] We used neutral loss scanning with highstringency target-decoy analysis to identify phosphorylation sites present in exosomal proteins from human urine samples.
Nineteen phosphorylation sites corresponding to 14 phosphoproteins were identified (Table 5 ). These included both newly identified phosphorylation sites and sites that had been previously identified. Two orphan G-protein-coupled receptors are included in the former group, viz. GPRC5B and GPRC5C. In GPRC5B, we identified one new phosphorylation site, T389, and, in GPRC5C, we identified three new phosphorylation sites, T435, S395, and Y426. These proteins are also known as retinoic acid-induced gene 2 (GPRC5B) and retinoic acid-induced gene 3 (GPRC5C).
A new phosphorylation site was also identified in the COOH-terminal tail of the thiazide-sensitive co-transporter (NCC) at S811 (Figure 2 ). This site is distinct from the Nterminal site previously identified 14 and may play a role in regulation of transport. This amino acid is conserved in humans, chimpanzees, rhesus monkeys, and horses but not in mice and rats. Simon et al. 15 showed that, in rat, the amino acid sequence surrounding this site is absent owing to a difference in exon splicing. Novel phosphorylation sites were also identified in RRAS2 (TC21), VPS4B (an ESCRT component), cytochrome b reductase, proteasome ␣ 3 subunit, and mucin 1. This study also revealed previously identified phosphorylation sites in AQP2 (S256), 16 NKCC2 (T118 and S120), 17 CHMP2B (S199), 18 HSP90AB1 (S255), 19 and SPP1 (S192, S197, and S207). 20 Phosphorylation of AQP2 at S256 was confirmed by immunoblotting human urinary exosomes samples with a phospho-specific antibody for this site (Figure 3 ).
DISCUSSION
Large-Scale Proteomic Profiling of Human Urinary Exosomes
One of the objectives of this study was to expand the existing human urinary exosome database by using a higher sensitivity LC-MS/MS mass spectrometer and improved computational tools for matching spectra to proteins in the human proteome. The LTQ mass analyzer has an increased trapping efficiency, ion capacity, and ion ejection rate compared with the LCQ mass analyzer 1 used in our previous study. We identified the peptide sequences using the SEQUEST program and analyzed them using the target-decoy database search strategy and the InsPecT tool. The target-decoy database search strategy allows adjustment of SEQUEST search parameters to ensure a given false-discovery rate (FDR). 13 The InsPecT tool uses de novo sequencing to generate tag filters, which are then used to search the database to "look for any peptide that matches the tag." 21 The data have been made available to the general public and can be downloaded from our laboratory's website (http://dir.nhlbi.nih.gov/papers/lkem/exosome/). In addition, the database can be searched using the BLAST algorithm.
As illustrated in Figure 1 , analysis of human urinary exosomes by mass spectrometry and immunoblotting can provide information with regard to genetic diseases involving apical proteins as shown by the qualitative assessment of urinary exosome samples from patients with Bartter syndrome type I. The a Information for each protein include "Gene" name, "Protein Name", "Pep" refers to the number of unique peptides identified in LC-MS/MS, "ID" refers to the number of spectra and "Related to Disease ͓OMIM͔" refers to the disease with which the protein is related according to OMIM. The 34 proteins associated with kidney diseases are presented in italics.
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Barriers to Clinical Use of Human Urinary Exosome Analysis
We previously reviewed the potential of urinary exosome analysis as a route to biomarker discovery in renal diseases and delineated barriers to success with the approach. 2, 21, 22 One important barrier is the lack of standard protocols for collection, processing, and storage of urine samples to allow reproducible measurements to be made in any clinical laboratory. We have proposed a set of procedures that can serve as a beginning point in the development of such techniques (http://intramural. niddk.nih.gov/research/uroprot/). Our current approach includes an ultracentrifugation step, which requires expensive instrumentation and long processing times. Filtration methods have been proposed to replace the ultracentrifugation step. 3 A particular knotty problem is removal of Tamm-Horsfall protein, an extraordinary abundant urinary protein that interferes with successful mass spectrometry and immunoblotting. 23 In the long run, the most important technical challenge may be to develop quantification approaches that allow detection of changes in excretion rates of particular biomarker candidates. Both labeling and nonlabeling methods have been developed to make protein mass spectrometry quantitative 24 ; however, the biggest barrier to quantification lies in development of adequate normalization techniques providing surrogates for timed collections of urine, which are notoriously inaccurate. 21 Use of creatinine as a normalizing variable may be inadequate because of high subject-tosubject variability in its rate of excretion. 21 Even without quantification, urinary exosome analysis can be valuable in situations such as genetic diseases (e.g., Bartter syndrome type I [ Figure 1] ), where a protein may be entirely absent from urinary exosomes.
Relevance to Renal Biology
Several of the proteins newly identified in urinary exosomes in this study may have considerable relevance to renal biology and the mechanism of renal disease. Our previous study 1 identified proteins that were characteristic of most of the cell types facing the urinary space from podocytes through transitional epithelial cells of the urinary drainage system. In this study, we identified markers of two additional cell types, type A and B intercalated cells. Specifically, the B1 subunit of the H ϩ -ATPase is apically located in type A intercalated cells, 25 and the anion transporter pendrin is present in type B intercalated cells. 26 Previously, we showed that urinary exosomes are derived from the apical endosomal pathway so that, although the B1 subunit of the H ϩ -ATPase is also expressed in type B intercalated cells, its basolateral location probably precludes delivery to urinary exosomes. Overall, we identified 17 different vacuolar H ϩ -ATPase subunits in urinary exosomes, 78% of the whole V 0 -V 1 complex. 8 We identified all of the subunits of the four ESCRT complexes (ESCRT-0 through ESCRT-III) in urinary exosomes in this study. The ESCRT complexes play a central role in the formation of MVB and the secretion of exosomes. 5 Four different orphan G-protein-coupled receptors were identified in urinary exosomes in this study, namely GPR98, GPRC5A, GPRC5B, and GPRC5C. These receptors are presumably apically located in one or more renal tubule cells. GPR98 (also known as very large G-protein-coupled receptor 1 or Neurepin) has more than 6000 amino acids. The three GPRC5 proteins are members of the metabotropic glutamate family, but their natural ligands are unknown. It will be of interest in future studies to discover the role of these proteins in renal development and regulation.
Phosphoproteomic Analysis of Human Urinary Exosomes
Posttranslational modifications (PTM) of proteins play an important role in protein function. Among the most important PTM is phosphorylation. Protein phosphorylation regulates cellular signaling processes and may determine protein structure, function, and subcellular localization. 12 The ability to detect PTM, such as phosphorylation, in urinary exosomes may provide an additional level of information that could aid in diagnosis and treatment of a variety of renal disorders. Furthermore, discovery of PTM in urinary exosomes can provide clues about physiologic and pathophysiologic mechanism. In this study, we identified 14 phosphoproteins. The specific phosphorylation sites identified included six that were previously identified and eight that had not been previously identified. Among the novel sites was serine-811 in the NCC protein. This amino acid is conserved in humans, chimpanzees, rhesus monkeys, and horses but not in mice and rats. The amino acid sequence surrounding this site is absent in rodents owing to a difference in exon splicing. 15 Finally, AQP2 phosphorylated at serine-256 was readily detectable in urinary exosomes. Because this phosphorylation event is increased by vasopressinstimulated activation of adenylyl cyclase, 16 measurements of the amount of serine-256 -phosphorylated AQP2 in urine may provide an improved means of assessing the state of vasopressin activation using phospho-specific antibodies.
CONCISE METHODS
Urinary Exosome Isolation
Urine was collected from eight healthy humans: Four men (aged 22 to 33) and four women (aged 24 to 35) (National Institute of Diabetes and Digestive and Kidney Diseases Clinical Research Protocol 00-DK-0107). Fifty milliliters per subject was collected and mixed together. The urinary exosome isolation procedure is shown in Figure 4 . Protease inhibitors were added (1.67 ml of 100 mM NaN 3 , 2.5 ml of 11.5 mM 4-[2-aminoethyl] benzenesulfonyl fluoride, and 50 l of 1 mM leupeptin). The mixed sample was centrifuged at 17,000 ϫ g for 10 min at 4°C. The 17,000 ϫ g supernatant was ultracentrifuged at 200,000 ϫ g for 1 h at 25°C. The ultracentrifugation step was repeated 3 additional times, adding new 17,000 ϫ g supernatant volume each time to each of the 12 tubes. Each of the 12 pellets was suspended with 50 l of "isolation solution" (10 mM triethanolamine and 250 mM sucrose). The suspensions were pooled together. The abundant urinary protein uromodulin or Tamm-Horsfall protein forms very high molecular weight complexes through disulfide linkages. These complexes sediment in the 200,000 ϫ g spin unless denatured. To denature the zona pellucida domains in the Tamm-Horsfall protein, we mixed the resuspended pellet with 200 mg/ml dithiothreitol (DTT) at 95°C for 2 min. The resuspended pellet was added to an ultracentrifuge tube, and isolation solution was added to increase the volume to 8 ml. The sample was centrifuged at 200,000 ϫ g for 1 h at 25°C. The pellet was suspended in 50 l of isolation solution and frozen at Ϫ80°C. BASIC RESEARCH www.jasn.org Table 5 . Proline-directed BASIC RESEARCH www.jasn.org Table 5 . BASIC RESEARCH www.jasn.org
In-Gel Trypsin Digestion
The protein concentration was determined using the Bradford Assay. This sample was solubilized in Laemmli sample buffer (1.5% SDS, 6% glycerol/10 mM Tris HCl, and 60 mg/ml DTT). Proteins in the exosome sample were separated by 1D SDS-PAGE using a Bio-Rad Ready Gel 4 to 15% polyacrylamide gradient gel with 125 g distributed among two lanes. The gel was stained with Colloidal Coomassie Blue (GelCode Blue Stain Reagent; Pierce, Rockford IL) for 10 min and destained using ddH 2 O (2 ϫ 30 min). The gel was divided from top to bottom into 40 1-mm strips over the entire molecular weight range of the gel. Each strip was diced into small pieces (1 mm 3 ) and placed into labeled centrifuge tubes.
The gels pieces were destained by adding 100 l of 25 mM ammonium bicarbonate (NH 4 HCO 3 )/50% acetonitrile (ACN) for 10 min and were dried using a SpeedVac. The samples were reduced in a solution of 10 mM DTT and 25 mM NH 4 HCO 3 at 56°C for 1 h. The samples were alkylated in a solution containing 55 mM iodoacetamide and 25 mM NH 4 HCO 3 in the dark at room temperature for 45 min. The gel pieces were washed with 25 mM NH 4 HCO 3 and dehydrated in a solution containing 25 mM NH 4 HCO 3 and 50% ACN. The samples were dried using the SpeedVac. The samples were rehydrated in a solution containing 12.5 ng/l trypsin (V5113; Promega, Madison, WI) in 25 mM NH 4 HCO 3 and digested overnight at 37°C. Peptides were extracted using 50% ACN/0.1% formic acid (FA). The extracted samples were dried using the SpeedVac to remove ACN and then reconstituted with 0.1% FA. All 40 peptide samples were desalted using C 18 Zip Tips (Millipore, Billerica, MA) before analysis by mass spectrometry.
Nanospray LC-MS/MS
A high-sensitivity linear ion trap mass spectrometer, LTQ (Thermo Electron Corp.) equipped with a nanoelectrospray ion source was used to acquire m/z ratios in both precursor ions (MS1) and fragmented ions (MS2) scans. To reduce further the sample complexity before mass analysis, we injected the tryptic peptides extracted from each gel slice using an Agilent 1100 nanoflow system (Agilent Technologies, Palo Alto, CA) into a reversed-phase liquid chromatographic column (PicoFrit, Biobasic C 18 ; New Objective, Woodburn, MA). This LC-MS/MS method allows the acquisition of raw data files that are the MS/MS scans of the five highest intensity peaks after IMCD exo fragmentation with collision-induced dissociation in the LTQ mass analyzer.
Analysis of Data
The raw data files were searched against the NCBI Reference Sequences (RefSeq) human protein database by using BIOWORKS software (Thermo Finnigan). BIOWORKS utilizes SEQUEST, which is a program that "finds database candidate sequences whose theoretical spectra are compared with the experimental spectrum." 27 To identify thoroughly peptide sequences, we searched the raw data files using the target-decoy approach and InsPecT. In addition, we analyzed the data in a two-step process. The first step was to assess and minimize false-discovery peptide identifications using the target-decoy approach, manual inspection of spectra, and InsPecT. The second step was to assess and eliminate ambiguous protein identifications.
Target-Decoy
To apply the target-decoy database searching strategy, 13 we used the NHLBI Proteomics Core Facility in-house software to create a composite database containing the forward and reverse sequences of the nonredundant NCBI Reference Sequences (RefSeq) human protein database released on January 26, 2007. We used the forward sequences as the target database and the reversed sequences as the decoy database. We searched the raw data files against this composite database. After the search, we assessed the FDR by the number of peptides matched from the reversed sequences. The parameters that determine the stringency of the filtering criteria include XCorr, Sp rank, and delta Cn. These parameters were incrementally adjusted, thereby reducing the false-discovery identifications until a target FDR was achieved. In our case, the data were filtered to a target of 2% FDR, and the actual FDR was 1.91%. The filter settings used were min Xcorr rank 1, min Sp rank 10, min delta Cn 0.08, charge ϩ 1 min Xcorr 2.37, charge ϩ 2 min Xcorr 2.87, and charge ϩ 3 min Xcorr 3.37.
InsPecT
We performed an additional analysis of the tandem mass spectrometry data using the InsPecT tool. 28 InsPecT uses de novo sequencing to generate sequence information (tag filters) from the experimental data. The tag filters are used to search the human protein database, nonredundant NCBI Reference Sequences (RefSeq) human protein database released on January 26, 2007, and identify peptide sequences that match with the experimental data. The size of the tag filters are three peptides in length on average. As shown in Figure 5 , the tag filter generated for the protein CHMP1A matches the experimental data accurately. The peptide sequences identified using the tag filters are then scored to estimate that the top match is correct. 28 The score procedure computes the P value for each peptide sequence by "comparing the match quality score to the distribution of quality scores for incorrect matches." For these data, we accept only peptide matches with P Յ 0.05.
Minimizing False-Discovery Peptide Identifications
In addition to the target-decoy approach the InsPecT analysis, we validated the quality of proteins identified by manually checking the spectra of those proteins with one unique peptide. We filtered out the proteins that did not have the expected molecular weight that matched to the corresponding regions in the 1-D SDS PAGE.
Elimination of Ambiguous Protein Identifications
Once proteins were identified using the approaches described, we needed to determine whether all identifications corresponded to unique gene products. An "ambiguous identification" is defined as an identification for which the peptide sequence that is used to determine the protein identity is found in multiple proteins that are not splice variants of the same gene ( Figure 6 ).
To disambiguate the data set, we generated software that automates the comparison of each peptide sequence to the protein sequences in the RefSeq Human Protein Database using the BLAST algorithm. An identification was considered unambiguous when the sequence was a 100% match without gaps to one and only one protein ( Figure 6A ). An identification was also considered unambiguous when the sequence was a 100% match without gaps to more than one protein but these proteins are splice-variant products of one unique gene ( Figure 6B ). An identification was considered ambiguous when a peptide sequence was a 100% match without gaps to more than one protein deriving from more than one gene and the identification was BASIC RESEARCH www.jasn.org based only on that single peptide ( Figure 6C ). The proteins identified from at least one unambiguous peptide were considered unambiguous proteins. The proteins that contained only ambiguous peptides were considered ambiguous proteins.
Patients with Bartter Syndrome Type I
We collected spot urine samples from two patients with clinically diagnosed Bartter syndrome type I. The patients were enrolled in the institutional review board-approved protocol 76-HG-0238. We obtained written informed consent from the parents and/or patient. We collected urine samples from healthy humans and used them as controls. We processed all samples using the differential centrifugation method to isolate human urinary exosomes described already. Each sample was prepared for immunoblotting by solubilizing in Laemmli buffer (1.5% SDS, 6% glycerol, 10 mM Tris HCl, and 60 mg/ml DTT). The samples, patient 1 and patient 2, and the control samples, control 1 and control 2, were loaded onto a 1-D SDS-PAGE gel on the basis of time as measured by creatinine excretion. The proteins were transferred to Immobilon-P (Millipore) membranes, blocked, and probed with antigen-specific NKCC2 and NCC primary antibodies. We incubated the blots with species-specific fluorescence secondary antibodies (Alexa 688) and visualized them using the Odyssey Infrared Imaging System (LiCor, Lincoln, NE).
Phosphopeptide Enrichment and LC-MS/MS Analysis
We collected urine specimens (200 ml) from six healthy humans, three men and three women. We processed the specimens 400 ml/d for 3 d and pooled them. The exosome isolation was as described previously except that phosphatase inhibitors 10 mM NaF (Sigma, St. Louis, MO), 20 mM ␤-glycerol phosphate (Fluka, St. Louis, MO), and 1 mM sodium orthovanadate (Sigma) were added. The pellet was resuspended in 6 M guanidine HCl/50 mM NH 4 HCO 3 .
The sample was concentrated using a Centricon tube at 13,500 ϫ g, with a starting volume of 420 l and a final volume of 55 l. The sample was reduced with 50 mM DTT for 1 h at 56°C. The sample was alkylated by addition of 100 mM iodoacetamide for 1 h (dark) at room temperature and was digested with trypsin overnight at 37°C. The sample was centrifuged at 16,000 ϫ g for 20 min. The supernatant was kept, and 100% FA was added to inactivate the trypsin. The sample was desalted on a 1-ml HLB column (Waters Oasis, Milford, MA) by positive displacement via a syringe with a luer adapter. The sample was eluted with two elution buffers. Elution buffer 1 contained 50% ACN and 0.1% FA, and elution buffer 2 contained 90% ACN and 0.1% FA. The eluents, 50 and 90%, were dried using the SpeedVac.
Phosphopeptides were enriched from the samples using the Pierce Phosphopeptide Isolation Kit (cat. no. 89853) according to the manufacturer's protocol. Phosphopeptide samples were desalted using C 18 ZipTips (Millipore) before analysis by mass spectrometry. Phosphopeptide samples were analyzed on an Agilent 1100 nanoflow system (Agilent Technologies) LC connection to a Finnigan LTQ FT mass spectrometer (Thermo Electron) equipped with a nanoelectrospray ion source as described previously. 11 The five most intense ions were sequentially isolated and fragmented (MS2) in the linear ion trap using collision-induced dissociation. The data-dependent neutral loss algorithm in XCALIBUR software was used to trigger an MS3 scan when a neutral loss of 98.0, 49.0, or 32.7 Da was detected among the two most intense fragment ions in a given MS2 spectrum. An unambiguous identification when a peptide sequence was a 100% match without gaps to more than one protein, but these proteins are splice-variant products of one unique gene. (C) An ambiguous identification when a peptide sequence was a 100% match without gaps to more than one protein deriving from more than one gene, and the identification was based only on that single peptide.
